Mease, Philip J. http://orcid.org/0000-0002-6620-0457
Gottlieb, Alice B. http://orcid.org/0000-0002-2927-8618
Ogdie, Alexis http://orcid.org/0000-0002-4639-0775
McInnes, Iain B. http://orcid.org/0000-0002-6462-4280
Chakravarty, Soumya D. http://orcid.org/0000-0001-7957-838X
Rampakakis, Emmanouil http://orcid.org/0000-0002-7427-8246
Kollmeier, Alexa http://orcid.org/0000-0002-2059-7866
Xu, Xie L.
Shawi, May http://orcid.org/0000-0001-6005-3938
Lavie, Frederic http://orcid.org/0000-0002-5213-257X
Kishimoto, Mitsumasa http://orcid.org/0000-0002-4007-1589
Rahman, Proton http://orcid.org/0000-0002-4521-2029
Funding for this research was provided by:
Janssen Global Medical Affairs
Article History
Received: 29 June 2023
Revised: 17 August 2023
Accepted: 18 August 2023
First Online: 3 October 2023
Ethics approval
: The DISCOVER-2 trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was approved by each site’s governing ethical body, and all patients provided written informed consent.
: <b>PJM</b> has received research support, consulting fees, and/or speaker bureau support from AbbVie, Acelyrin, Aclaris, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Inmagene, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Sun Pharma, UCB, Ventyx, and Xinthera. <b>ABG</b> has received honoraria as an advisory board member and consultant for Amgen, AnaptypsBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly, Janssen, Novartis, Sanofi, UCB, and Xbiotech, and has received research/educational grants from AnaptypsBio, Bristol Myers Squibb, Moonlake Immunotherapeutics AG, Novartis, and UCB (all paid to Mount Sinai School of Medicine). <b>AO</b> has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, Happify Health, Janssen, Novartis, Pfizer, and UCB; grant/research support to the University of Pennsylvania from AbbVie, Janssen, Novartis, and Pfizer, and to Forward from Amgen. Her husband has received royalties from Novartis. <b>IBM</b> has received consulting fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Roche, and UCB; and is a shareholder of Causeway Therapeutics, and Evelo Compugen, <b>SDC</b> is an employee of Janssen Scientific Affairs, LLC and owns stock or stock options in Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. <b>ER</b> is a consultant of Janssen and an employee of JSS Medical Research. <b>AK</b> is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stocks in Johnson & Johnson. <b>XLX</b> is an employee of Janssen Research & Development. <b>MS</b> is an employee of Janssen Research & Development and owns stock or stock options in Johnson & Johnson. <b>FL</b> is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies and owns stock in Johnson & Johnson. <b>MK</b> has received consulting fees and/or speakers fees from AbbVie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Tanabe-Mitsubishi, and UCB. <b>PR</b> has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; travel support from Janssen; and grants from Janssen, and Novartis.